Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Ekinci, İskender; Büyükkaba, Mitat; Çınar, Ahmet; Tunç, Muhammed; Cebeci, Egemen; Gürsu, Meltem; Kazancıoğlu, Rümeyza

doi:10.7759/cureus.13561

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated elevated plasma endocan levels in polycystic kidney disease, immunoglobulin A nephropathy, chronic kidney disease, and hypertension (11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 96%

Endocan Levels in Children with Polycystic Kidney Disease

Aydin¹,

Aygar²,

Bayrakçı³

et al. 2022

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

Objective: Autosomal dominant polycystic kidney disease (ADPKD) is a common renal disorder that is characterized by hypertension and renal failure. Recently, it has been emphasized that endocan which is an endothelial dysfunction biomarker, could increase in many renal diseases. High endocan levels have also been reported in hypertensive ADPKD adult patients with renal failure. However, studies are limited on children. In this study, we investigated the serum endocan levels in normotensive ADPKD children with normal renal function. Material and Methods:The study consisted of 20 ADPKD children without hypertension and renal failure as a patient group, and 20 healthy age-and sex-matched children as a control group. Serum endocan levels were determined by enzyme-linked immunosorbent assay techniques and compared between the two groups. Results:The mean age of patients was 9.9±4.12 years, and the mean age of the control group was 10.2±3.83 years. There was no significant difference between the two groups in terms of gender, age, and BMI (p=0.751, p=0.813, p=0.781, respectively). The leukocyte (p=0.449), hemoglobin (p=0.337), platelets (p=0.134), serum uric acid (p=0.671) and serum creatinine (p=0.074) levels, eGFR (p=0.459) were not significantly differed between groups. The mean serum endocan level in the PKD group was 345.8±169.5 pg/ml, and in the control group was 448.61±258.2 pg/ml. Serum endocan levels did not change between groups (p=0.159). Conclusion:Unlike the adult ADPKD patients, this study suggested that serum endocan level was normal in children with ADPKD without hypertension and renal failure.

show abstract

“…Previous studies have demonstrated elevated plasma endocan levels in polycystic kidney disease, immunoglobulin A nephropathy, chronic kidney disease, and hypertension (11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 96%

Endocan Levels in Children with Polycystic Kidney Disease

Aydin¹,

Aygar²,

Bayrakçı³

et al. 2022

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

show abstract

“…Endocan combined with angiopoietin-1 and HF-1a could be emerging biomarkers for patients at the early stages, having potential utility for the assessment of the disease progression. Recently, Ekinci et al conducted a study with 51 ADPKD and 20 hypertensive patients to evaluate endothelial dysfunction and atherosclerosis in terms of endocan, ADMA levels, flow-mediated dilatation (FMD), nitroglycerin-mediated dilation (NMD), and carotid intima-media thickness (CIMT) [ 78 ]. Although no significant difference was found in serum endocan levels between ADPKD and hypertensive patients, in ADPKD patients with eGFR≤60 ml/min/1.73 m 2 , serum endocan levels were significantly higher than those in patients with eGFR>60 ml/min/1.73 m 2 .…”

Section: Endocan and Kidney Diseasesmentioning

confidence: 99%

Prognostic and Diagnostic Value of Endocan in Kidney Diseases

Samouilidou

Athanasiadou

Grapsa

2022

International Journal of Nephrology

View full text Add to dashboard Cite

Endocan, previously called endothelial cell-specific molecule-1, is a soluble proteoglycan that is predominantly expressed in vascular endothelial cells of the lungs and kidneys. It is upregulated by proinflammatory cytokines and plays a critical role in inflammatory, proliferative, and neovascularization processes. The utility of endocan as a biomarker in a wide spectrum of diseases is being increasingly acknowledged. In this review, we summarize the current evidence concerning the role of endocan in kidney diseases, with emphasis on its prognostic and diagnostic value. It seems that the determination of plasma endocan levels may provide useful prognostic information in many types of renal failure such as chronic kidney disease, IgA nephropathy, and diabetic nephropathy. Endocan could additionally improve the early diagnostic evaluation of acute kidney disease, chronic renal allograft injury, and acute rejection after kidney transplantation, thus contributing to endothelial cell injury monitoring in a timely manner.

show abstract

“…Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common monogenic disorder with an increasing prevalence in the last decade [1,2]. The patients affected by ADPKD are characterized by progressive formation of cysts in the kidneys with progressive renal failure; in addition, more than half suffer from an increased predisposition to atherosclerosis, chronic inflammation, and show a higher risk of cardiovascular disease [3]. Although a fully reliable disease marker is still missing, several biochemical markers that can be assayed in patients' blood and urine such as albumin, creatinine and total proteins [4].…”

Section: Introductionmentioning

confidence: 99%

Exploring Adiponectin in Autosomal Dominant Kidney Disease: Insight and Implications

Nigro,

Mallardo,

Amicone

et al. 2024

Genes

View full text Add to dashboard Cite

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common monogenic disorder characterized by renal cysts and progressive renal failure. In kidney diseases, adipose tissue undergoes functional changes that have been associated with increased inflammation and insulin resistance mediated by release of adipokines. Adiponectin is involved in various cellular processes, such as energy and inflammatory and oxidative processes. However, it remains to be determined whether adiponectin is involved in the concomitant metabolic dysfunctions present in PKD. In this scenario, we aimed to analyze: (a) PPARγ, ADIPOQ, ADIPOR1 and ADIPOR2 gene variations in 92 ADPKD patients through PCR-Sanger sequencing; and (b) adiponectin levels and its oligomerization state by ELISA and Western Blot. Our results indicated that: (a) 14 patients carried the PPARγ SNP, 29 patients carried the ADIPOQ SNP rs1501299, and 25 patients carried the analyzed ADIPOR1 SNPs. Finally, 82 patients carried ADIPOR2 SNPs; and (b) Adiponectin is statistically lower in ADPKD patients compared to controls, and further statistically lower in ESRD than in non-ESRD patients. An inverse relationship between adiponectin and albumin and between adiponectin and creatinine and a direct relationship between adiponectin and eGFR were found. Interestingly, significantly lower levels of adiponectin were found in patients bearing the ADIPOQ rs1501299 SNP and associated with low levels of eGFR. In conclusion, adiponectin levels and the presence of ADIPOQ rs1501299 genotype are significantly associated with a worse ADPKD phenotype, indicating that both could potentially provide important insights into the disease. Further studies are warranted to understand the pathophysiological role of adiponectin in ADPKD patients.

show abstract

Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Cited by 3 publications

References 25 publications

Endocan Levels in Children with Polycystic Kidney Disease

Endocan Levels in Children with Polycystic Kidney Disease

Prognostic and Diagnostic Value of Endocan in Kidney Diseases

Exploring Adiponectin in Autosomal Dominant Kidney Disease: Insight and Implications

Contact Info

Product

Resources

About